Orthocell Ltd (OCC) AI Stock Analysis

• Market Cap: AU$280.78M
• Dividend Yield: N/A
• Average Volume (3M): 484.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: 42.05%
• EPS Growth: -0.84%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 246,300,000
• 10 Day Avg. Volume: 576,829
• 30 Day Avg. Volume: 484,530
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.50
• Price Target Upside: 31.58% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: AU$1.00 ▼(-12.28% Downside)

Orthocell Ltd's overall stock score is primarily influenced by its financial performance, which shows revenue growth but significant profitability and cash flow challenges. Technical analysis indicates a bearish trend, and the valuation reflects ongoing losses with a negative P/E ratio. The absence of earnings call and corporate events data limits additional insights.

Orthocell Ltd Business Overview & Revenue Model

Company Description

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

How the Company Makes Money

Orthocell Ltd generates revenue through the sale and licensing of its proprietary regenerative medicine products and technologies. The company's key revenue streams include the commercial distribution of CelGro for use in various surgical procedures and the provision of its cell therapy solutions, Ortho-ATI and Ortho-ACI, to healthcare providers and institutions. Additionally, Orthocell may engage in strategic partnerships and collaborations with other companies and research organizations, potentially contributing to its earnings through licensing fees, milestone payments, and royalties. The company's revenue model is underpinned by its focus on expanding market adoption and obtaining regulatory approvals to broaden its product offerings and geographic reach.

Orthocell Ltd Financial Statement Overview

Summary

Orthocell Ltd is experiencing revenue growth, but profitability remains a significant challenge with negative margins and returns. The balance sheet is stable with low leverage, but cash flow issues persist, impacting the company's ability to generate positive cash flow from operations.

Income Statement

Orthocell Ltd has shown a positive revenue growth rate of 19.57% in the latest year, indicating a growing top line. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has decreased slightly from the previous year, suggesting some pressure on cost management.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.04, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is healthy, suggesting a strong capital structure, but the negative ROE highlights profitability challenges.

Cash Flow

Orthocell Ltd has improved its free cash flow growth rate by 12.12%, but the operating cash flow remains negative, indicating cash flow challenges. The free cash flow to net income ratio is above 1, suggesting that the company is generating cash flow relative to its net losses, but the overall cash flow position is weak.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.40M	7.55M	5.32M	4.24M	1.53M	1.02M
Gross Profit	3.58M	4.80M	3.69M	3.06M	832.52K	299.88K
EBITDA	-11.77M	-13.43M	-11.68M	-9.93M	-11.52M	-11.67M
Net Income	-8.57M	-8.57M	-7.18M	-6.25M	-9.11M	-9.04M
Balance Sheet
Total Assets	35.24M	35.24M	26.62M	29.61M	37.90M	19.33M
Cash, Cash Equivalents and Short-Term Investments	28.62M	28.62M	20.61M	24.82M	11.02M	16.33M
Total Debt	576.89K	576.89K	689.69K	562.30K	507.56K	621.72K
Total Liabilities	20.67M	20.67M	22.08M	23.46M	27.99M	2.46M
Stockholders Equity	14.57M	14.57M	4.53M	6.15M	9.90M	16.87M
Cash Flow
Free Cash Flow	-8.94M	-9.04M	-7.45M	13.96M	-6.80M	-4.82M
Operating Cash Flow	-8.68M	-8.68M	-6.51M	14.59M	-6.26M	-4.63M
Investing Cash Flow	-359.06K	-359.06K	-942.02K	-631.56K	-535.02K	-188.52K
Financing Cash Flow	17.05M	17.05M	3.24M	-164.61K	1.49M	709.15K

Orthocell Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OCC, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.22, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.72 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OCC.

Orthocell Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCE	55 Neutral	114.23M	-4.38	0.00%	―	0.00%	0.66%
IMM	50 Neutral	366.97M	-5.92	0.00%	―	0.00%	-19.21%
DXB	46 Neutral	306.09M	-21.43	0.00%	―	1271.12%	36.87%
OCC	45 Neutral	AU$280.78M	―	-89.70%	―	42.05%	-0.84%
PAR	40 Underperform	117.36M	-5.73	0.00%	―	-20.79%	73.98%
ALA	40 Underperform	105.34M	-12.94	0.00%	―	700.00%	26.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Orthocell Ltd Corporate Events

Orthocell Expands Remplir’s Use in Prostate Cancer Surgeries

Orthocell Ltd has announced the use of its nerve repair device, Remplir, in nerve-sparing robotic-assisted radical prostatectomies (RARP) in Australia, aiming to reduce post-surgical complications such as erectile dysfunction and urinary incontinence. This development represents a significant opportunity for Orthocell to expand Remplir’s market presence, as the product is being adopted by urologists to protect and restore nerve function during prostate cancer surgeries, potentially increasing its global total addressable market.

The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Announces 2025 AGM and Director Nomination Deadline

Orthocell Limited has announced that its 2025 Annual General Meeting will be held on November 6, 2025, with the re-election of directors as a key agenda item. The closing date for director nominations is September 18, 2025. This announcement is part of Orthocell’s ongoing efforts to strengthen its governance structure as it continues to expand its market presence globally, particularly in the US with its regenerative medicine products.

The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell’s Remplir Study Shows 81% Success Rate, Boosting US and EU Expansion Plans

Orthocell Ltd has announced interim results from its Remplir Real World Evidence study, demonstrating an 81.1% overall treatment success rate in nerve repair procedures. The study supports the US sales rollout and regulatory submissions in the EU and UK, highlighting Remplir’s effectiveness in real-world settings. The data shows significant improvements in muscle recovery and symptom relief, with no reported complications, reinforcing Remplir’s clinical success and its adoption by over 200 surgeons in more than 165 hospitals.

The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Expands Share Base with New Issuance

Orthocell Limited has issued 1,500,000 fully paid ordinary shares following the exercise of unlisted options, allowing these shares to be traded immediately. This move is part of the company’s compliance with the Corporations Act, potentially enhancing its market operations and providing liquidity for stakeholders.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Issues New Securities to Strengthen Market Position

Orthocell Ltd has announced the issuance of 1,500,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code OCC. This move is part of the company’s strategic efforts to enhance its capital structure, potentially strengthening its market position and providing additional resources for its ongoing projects in regenerative medicine.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Appoints New Director, Strengthening Strategic Direction

Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options and 56,169 ordinary fully paid shares through McNulty Family Pty Ltd and his spouse, indicating a significant personal investment in the company. This appointment may enhance Orthocell’s strategic direction and strengthen its position in the regenerative medicine sector.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Issues Unquoted Options to Enhance Strategic Flexibility

Orthocell Ltd announced the issuance of 2,000,000 unquoted options, set to expire on August 31, 2028, with an exercise price of $1.53. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s capital structure and offering strategic flexibility in its financial operations.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Appoints New Director, Enhancing Leadership

Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options through McNulty Family Pty Ltd, exercisable at $1.53 and expiring on August 31, 2028. This appointment is expected to strengthen the company’s leadership team, potentially impacting its strategic direction and stakeholder relations positively.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.